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Abstract 
Cardiovascular disease is highly prevalent in modern 
western societies and aspirin has been established as an 
irreplaceable drug in such patients. A small but non-negligible 
number of these patients, manifest hypersensitivity to aspirin and 
/or other non-steroidal anti-inflammatory drugs (NSAIDs), 
which can take different forms depending on the underlying 
pathophysiology and clinical variability. In this brief 
communication, we review the types of hypersensitivity to 
NSAIDs, the diagnostic steps and its management, focusing on 
desensitization protocols in patients who require coronary 
interventions and long-term salicylate administration. Rhythmos 
2018;13(2);30-34.   
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Abbreviations: CAD = coronary artery disease; COX-1 = 
cyclooxygenase-1; NSAIDs = non-steroidal anti-inflammatory 
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Introduction 
Coronary artery disease (CAD) is the leading cause of 
death in both genders in Western societies. The prevalence 
of clinically overt CAD is related to age and ranges from 
below 1% in individuals <40 years old up to over 30% in 
octogenarians. 1 The incidence of ST elevation myocardial 
infarction (STEMI) in Europe lies between 43 and 144 per 
100 000 per year, 2 while that of acute coronary syndromes 
between 1/80 and 1/170 per year. In all these patients who 
make up a considerable number, aspirin constitutes the 
mainstay of antithrombotic therapy; needless to say, in the 
acute coronary syndrome setting, its administration has to 
be immediate since any delay might lead to clinical 
deterioration and adverse outcomes especially when an 
emergency coronary intervention is warranted.  
However, not every patient tolerates aspirin well. 
Hypersensitivity reactions may be observed in 0.6-5.7% of 
the general population, while in predisposed individuals 
this frequency can reach 11%. 3,4 In this brief communi-
cation, we review the pathophysiological mechanisms of 
non-steroidal drug hypersensitivity, and the potential 
preventive and therapeutic maneuvers in patients with 
CAD who have a strong indication for aspirin use.  
Types of aspirin hypersensitivity 
Hypersensitivity reactions to non-steroidal anti-
inflammatory drugs (NSAIDs) are not rare in the general 
population, since their prevalence ranges between 0.6% 
and 2.5%, while asthmatics are affected more often (4-
20%).  However, depending on the specific population 
studied and the type of the reaction, this frequency may 
vary significantly. If provocation tests are used, the 
diagnosis is established in 21%. 3 Non-steroidal anti-
inflammatory drugs are among the most common agents to 
produce hypersensitivity-related adverse effects, second 
only to antibiotics. Clinically, hypersensitivity reactions 
exert three main manifestations: respiratory, cutaneous and 
systemic, and can vary in terms of timing (immediate vs 
delayed) and severity. Exacerbation of respiratory disease 
may be noted in 4.3-20% of patients, with the high 
percentage observed in female patients with chronic 
rhinosinusitis, nasal polyps or severe asthma. 5-7 Among 
patients with chronic urticaria, a large portion reaching 
30% may experience clinical deterioration after NSAID 
use. Moreover, up to 1/3 of skin reactions related to 
NSAIDs can be attributed to immunological mechanism. 8   
With respect to pathophysiology, either a 
pharmacological or immunological mechanism may be 
involved, although both types can exist in the same patient 
on different occasions. Pharmacological reactions are the 
result of the cyclooxygenase-1 (COX-1) pathway 
inhibition, while immunological/allergic reactions are 
mediated by the production of drug specific 
immunoglobulin E (IgE) or sensitized T-cells. 9-11  
Non-allergic hypersensitivity reactions are typically 
cross-reactive (they involve reactions to several, 
chemically non-related NSAIDs) because COX-1 
inhibition is a common pharmacologic action shared by 
many chemically different NSAIDs. Cyclooxygenase 
catalyzes the production of prostaglandins and 
thromboxanes from arachidonic acid. Among the former, 
prostaglandin E2 plays a vital role in stabilizing 
inflammatory cells. Its deprivation therefore is believed to 
activate these cells, especially in susceptible individuals. 12 
Moreover, the 5-lipoxygenase pathway is enhanced, 
leading to the overproduction of leukotrienes, which can 
exacerbate respiratory symptoms. 13  
Non-immunologically mediated reactions can take any 
of the three forms: NSAIDs- exacerbated respiratory 
disease, NSAIDs exacerbated cutaneous disease or 
NSAIDs-induced urticaria/angioedema.14  
NSAID-exacerbated respiratory disease: Formerly 
known as Samter or Widal syndrome, it presents mainly as 
dyspnea, bronchial obstruction and nasal congestion, in 
individuals already suffering from an underlying 
respiratory disease, such as asthma, nasal polyps or 
rhinosinusitis. It typically relates to more than one drug of 
the category. 
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NSAID-exacerbated cutaneous disease: It manifests 
with angioedema or wheals in relation with aspirin or other 
NSAID, in patients with a history of spontaneous urticaria. 
NSAID-induced urticaria/angioedema: Clinical 
presentation is similar to the previous form, but the 
affected patients do not report a chronic urticaria history. 
Symptoms must be induced by at least two agents of the 
NSAID class originating from different chemical groups. 
Immunologic reactions occur after the administration 
of one or more substances belonging to the same chemical 
group. Typically, patients report no previous 
hypersensitivity episodes with the use of other NSAIDs. 
Two types of allergic phenomena are described:  
Single-NSAID-induced urticaria/angioedema or 
anaphylaxis is a rapid (within mins to 1 h) occurrence of 
symptoms ranging from mild urticaria to laryngeal edema 
and anaphylactic shock. It represents a type I allergic 
mechanism mediated by antigen-specific IgE antibodies. 
Single-NSAID-induced delayed hypersensitivity is 
characterized in the majority by cutaneous manifestations 
(maculopapular eruptions, photosensitivity reactions, 
delayed urticaria, contact dermatitis, acute generalized 
exanthematous pustulosis, and severe cutaneous adverse 
reaction-SCAR). Rarely may involvement of other organs 
be noted (nephritis, pneumonitis).15 This reaction is 
presumably a type IV immunological reaction occurring 
via the activation of specific CD4+ and CD8+ T cells as 
evidenced in several reports.16-18 This clinical and patho-
physiological classification is summarized in Table 1.  
Table 1. Classification of hypersensitivity reactions to NSAIDs10   
Reaction 
type  
Terminology Symptoms/ 
signs 
Timing Pathophy
siology 
Cross-
reactive 
(non-
immunolo
gically 
mediated) 
NSAID 
exacerbated 
respiratory 
disease 
Bronchial 
obstruction, 
dyspnea and/or 
nasal congestion/ 
rhinorrhea 
30-180 min Cox-1 
inhibition 
NSAID 
exacerbated 
cutaneous 
disease 
Wheals and/or 
angioedema 
30-360 min Cox-1 
inhibition 
NSAID-induced 
urticaria/ 
angioedema 
Wheals and/or 
angioedema 
15 min to 
hrs (usually 
within1 h) 
Unknown 
probably 
Cox-1 
inhibition 
Selective 
(immuno-
logically 
mediated) 
Single NSAID 
induced urticaria/ 
angioedema/ 
anaphylaxis 
Wheals/ 
angioedema/ 
anaphylaxis 
Immediate 
(typically 
within 1h) 
IgE-
mediated 
Single NSAID 
induced delayed 
hypersensitivity 
reactions 
Various 
symptoms and 
organs involved 
(e.g. fixed drug 
eruption, SJS/ 
TEN, nephritis) 
Delayed 
onset 
(usually 
>24 h after 
exposure) 
T-cell 
mediated 
 
NSAID = nonsteroidal anti-inflammatory drugs; SJS/TEN = 
Stevens-Johnson syndrome/toxic epidermal necrolysis  
Diagnosis  
Obtaining a detailed history is fundamental, as it 
provides information on the suspect drug, the type of the 
reaction and the presence of long-term symptoms. Then, 
according to the suspected reaction, provocative tests can 
be implemented to confirm the clinical diagnosis. In more 
detail, in exacerbated respiratory disease, oral provocative 
test is a sensitive method (sensitivity 90%) to detect 
hypersensitivity to aspirin or other drugs. Inhalation tests 
or nasal challenge with lysine-aspirin are quick and safe, 
but less sensitive. Cutaneous disease exacerbation is also 
confirmed by oral provocation. Interestingly, skin tests 
have no place in the diagnostic work-up. NSAID-induced 
urticaria/angioedema is suspected when the symptoms are 
related to the administration of at least two chemically 
different NSAIDs and no history of chronic urticaria is 
reported. Confirmation may be provided by oral 
provocative test with the culprit agent and in the case of 
aspirin with one alternative drug as well. 14, 19,20 Allergic 
reactions are usually diagnosed based on history of rapid 
onset of symptoms after exposure to a specific NSAID. A 
skin test with an alternative drug may be performed to 
exclude cross-reactivity. For the diagnosis of delayed 
hypersensitivity, patch tests or intradermal skin tests can 
be used.21-25  
In general, oral tests with the culprit agent are the gold 
standard for diagnostic confirmation. They exhibit both a 
high positive (almost 100%) and negative predictive value 
(97.8%). 20 However, they should not be performed in 
certain circumstances such as in severe delayed type 
reactions, in cases with a history of severe anaphylaxis, 
when the underlying chronic disease (asthma, urticaria) is 
uncontrolled and if concomitant disorders that could be 
aggravated by challenge are present. Usually the challenge 
is done with aspirin and an alternative drug to confirm or 
exclude cross-reactivity. Based on these general rules, 
Kowalski et al have proposed a seven-step diagnostic 
approach 15 which is depicted in Table 2.  
Table 2. Seven steps leading to the diagnosis of NSAIDs 
hypersensitivity 11  
History 1. Is it a predictable or unpredictable reaction? 
2. Assess the timing of the reaction 
3. Observe the clinical manifestations and the 
presence of chronic underlying disease 
4. Review the history for tolerance of other NSAIDs 
Tests 5. Confirm/exclude cross-reactivity to other NSAIDs 
by oral challenge 
6. Consider skin testing or in vitro testing in case of 
single reactions 
7. Consider oral provocation challenge with the 
culprit drug 
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Management  
Avoidance of the agent responsible for the reaction is 
fundamental. In single drug reaction, alternative NSAIDs 
can be used but it is prudent to perform an oral challenge 
in order to exclude cross-reactivity. Moreover, non-
acetylated salicylates such as trisalicylate or salsalate are 
well tolerated by most patients with respiratory disease 
exacerbations. 14 However, patients who suffer an acute 
coronary syndrome or undergo coronary angioplasty and 
stenting, cannot substitute aspirin as it constitutes the 
mainstay of antiplatelet therapy. In these cases, 
desensitization to aspirin can be attempted. Unfortunately, 
not all types of hypersensitivity are prone to 
desensitization procedures. These protocols have been 
validated in cases of exacerbation of respiratory disease 
and aspirin-induced urticaria/angioedema. 26-28 In 
exacerbated cutaneous disease the data are controversial 
and in immunological reactions no recommendations can 
be made due to the lack of evidence from prospective 
controlled trials. 29,30   
Desensitization  
Desensitization therapy refers to the elimination of 
pharmacological and immunologic reactions of aspirin by 
slowly increasing exposure to oral acetylsalicylic acid. The 
result is the decrease in leukotriene production, down-
regulation of cysteinyl leukotriene receptors, as well as 
extracellular histamine and tryptase levels after mast cell 
stimulation. In patients with IgE-mediated reactions, the 
exact mechanism is unknown, but repeated and sustained 
administration of aspirin leads to saturation of the specific 
IgE antibodies sites on basophils and mast cells. As an 
additive effect, cross-linking of IgE antibodies limits mast 
cell and basophil activation. Finally, intracellular 
mediators (i.e., histamine) are being depleted and the 
reaction gradually weakens and ceases. 31-33  
Although the available evidence supports 
desensitization in cases of aspirin-induced exacerbated 
respiratory disease and urticaria/angioedema, most 
patients with salicylate hypersensitivity can undergo the 
procedure, except for those with exacerbated cutaneous 
disease or induced delayed hypersensitivity. Several 
desensitization protocols have been used and there is no 
consensus yet for the use of a common methodology. 
Tables 3 and 4 describe the desensitization sequences 
implemented by Szczeklik and Stevenson, 34 Schaefer and 
Gore, 35 and Wong et al. 36  Silberman et al used two similar 
schemes in their patients who presented with acute 
coronary syndromes mostly treated with percutaneous 
intervention. The first consisted of 8 doses, starting at 1 mg 
and doubling every 30 minutes up to a final dose of 100 
mg (total duration 3.5 hours). The second was shorter, and 
was completed in 5 doses of 5, 10, 20, 40, and 75 mg. 37 
Christou et al reported on 11 patients with respiratory or 
cutaneous aspirin hypersensitivity who underwent 
coronary angioplasty (5 for stable angina, 3 for unstable 
angina, 2 for non-ST elevation myocardial infarction and 
1 for STEMI). They used the protocol proposed by Wong 
(Table 4) with complete success. Coronary interventions 
were all performed on the second day of admission. 38 
Rossini et al used a different rapid desensitization protocol 
with excellent results in 26 patients with respiratory or 
cutaneous manifestations undergoing percutaneous 
coronary intervention, which is displayed in Table 5. All 
patients were desensitized before intervention apart from 
those with STEMI who were subjected to the protocol 
before discharge. 39 A similar sequence was used by 
Schiano et al in a patient with a history of aspirin-induced 
urticaria/angioedema who presented with STEMI. The 
patient received thrombolytic therapy along with 
clopidogrel and heparin, and on the next day he was started 
on incremental doses of aspirin following a protocol 
lasting less than two hours (5, 10, 20, and 40 mg given at 
30 min intervals up to a cumulative dose of 75 mg, which 
was then continued daily. 40 Alternative protocols have 
also been tested. 41-44 All endorse oral administration of 
aspirin. Only one publication has introduced intravenous 
desensitization with administration of aspirin in doses of 1, 
2, 4, 8, 16, 32, 64, 125, 250 mg at time points 0, 30, 60, 90, 
120, 150, 180, 210, 240 min respectively. Efficacy was 
reported in 42 out of 43 patients (97.6%) over a 12-month 
follow up. 45   
Table 3. Desensitization protocol used in patients with ASA-
exacerbated respiratory disease 34  
Day       Time 0 3 hours 6 hours 
1 Placebo Placebo Placebo 
2 ASA 30 mg ASA 60 mg ASA 120 mg 
3 ASA 150 mg ASA 325 mg ASA 650 mg  
ASA = acetylsalicylic acid  
Table 4. Desensitization protocols used in patients with ASA-
induced cutaneous disease 35,36  
Wong et al protocol Schaefer and Gore protocol 
Time (min) ASA (mg) Time (h) Placebo/ASA (mg) 
0 
15 
30 
45 
60 
85 
110 
135 
0.1 
0.3 
10 
30 
40 
81 
162 
325 
0 
1 
2 
3 
4 
5 
6 
Placebo 
ASA 150 
ASA 325 
Placebo 
ASA 325 
Placebo 
End 
 
33 
 
 
Table 5. Rapid desensitization protocol proposed by Rossini et 
al. 39   
Time (min) Aspirin dose (mg) 
0 
30 
60 
90 
210 
330 
1 
5 
10 
20 
40 
100  
In a review of the available data, all studied regimens 
were found equally effective (success rate >97%). 
Reaction rate during protocol implementation did not 
exceed 5% and it was higher when the number of aspirin 
doses was <6 compared to less aggressive oral or IV 
protocols. Angioedema occurred in 3.4% (0.6%-6.3%) of 
the participants in relation with the short protocols only. 46  
Recently, the results of the ADAPTED multicenter 
registry were published. 47 A total number of 330 aspirin 
intolerant patients with stable CAD or acute coronary 
syndrome scheduled for percutaneous intervention were 
given the Rossini desensitization regimen before 
catheterization. In participants with STEMI (23%), 
desensitization was deferred until after the 
revascularization, and bridging therapy with IIb/IIIa 
inhibitors was given according to the judgment of the 
attending physicians. Desensitization was successful in 
315 patients (95.4%) and in all patients with a history of 
anaphylactic reaction. In the non-responder group (15 
patients-4.6%), adverse reactions were minor and were 
managed with corticosteroids and antihistamines. 47  
In conclusion, aspirin hypersensitivity is a relatively 
rare but recognizable condition which complicates the 
management of patients with CAD especially in cases of 
acute coronary syndromes requiring urgent intervention. 
Substituting triflusal for aspirin in dose 300 mg bid has 
been reported; 48 however it is seldom used. Rapid 
desensitization offers an attractive alternative and the 
literature has been encouraging so far. A variety of 
administration sequences with progressively increasing 
dose of aspirin have been tested and published with 
comparable, high efficacy, and this practice emerges as the 
most appropriate to deal with salicylate hypersensitivity 
when its long-term use is deemed necessary. Most 
protocols are completed within a few hours and can be 
applied before the coronary intervention. In case of 
STEMI, when any delay may be detrimental, primary 
angioplasty can be performed under IIb/IIIa inhibition and 
desensitization should follow. It should be also 
emphasized that the effect of desensitization fades away 
within a few days unless aspirin is uninterruptedly given 
thereafter, which must be taken into account when aspirin 
therapy is temporarily withheld as for instance in view of 
an upcoming surgical procedure. Although a promising 
method, desensitization has not been studied in large trials 
and its application is largely empiric or based on limited 
regional experience, as implied by the numerous similar 
protocols in use. Thus, more research is needed, which will 
allow for the incorporation of hypersensitivity 
management in current guidelines and will standardize the 
therapeutic approach in these patients.      
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